SecBot SecBot
Insider Cluster (4 insiders) ·Filed Jun 16, 2026

PCSA

Processa Pharmaceuticals, Inc.
BULLISH
Impact 5/10
Horizonweeks Processed4mo ago
Insider cluster: 4 insiders, $0.0M total
Actionable Insight ▲ Bullish

The coordinated C-suite buying at identical price and volume suggests management sees value at current levels. Monitor for upcoming pipeline catalysts (trial results, regulatory updates) that could re-rate the stock.

DirectionBullish
Confidencemedium
Horizonweeks
Final — all horizons settled through T+60d ⚠ clustered
PCSA ▼ -3.26% at T+60d
LONG call ✗ call lost -3.26% · α vs SPY -6.40% · entry $2.15 → $2.08
Entry = T+0 close
Jun 16, 2026
via day close
T+1d
-1.40%
call -1.40% · α -2.18%
$2.12
settled 4mo ago
T+5d
-10.23%
call -10.23% · α -9.19%
$1.93
settled 4mo ago
T+20d
+4.19%
call +4.19% · α +2.87%
$2.24
settled 3mo ago
T+60d
-3.26%
call -3.26% · α -6.40%
$2.08
settled 7w ago

Price Chart

Loading chart...

Executive Summary

Four C-suite insiders at Processa Pharmaceuticals (CEO, CFO, Chief Administrative Officer, Chief Business Strategy Officer) made open-market purchases totaling ~$20K on June 15, 2026, all at $2.22 per share. This cluster represents ~0.33% of the company's $6M market cap — a modest but notable vote of confidence from top management.

Key Financial Metrics

Direction
buying
Total Value
$20.0K
Insiders
4

Key Facts

  • CEO George K. Ng purchased 2,465 shares at $2.22 ($5,472).
  • CFO Russell Skibsted purchased 2,654 shares at $2.22 ($5,892).
  • Chief Administrative Officer Wendy Guy purchased 2,118 shares at $2.22 ($4,702).
  • Chief Business Strategy Officer Patrick Lin purchased 1,831 shares at $2.22 ($4,065).
  • Total insider purchases: ~$20K, or ~0.33% of $6M market cap.
  • Cluster occurred on a single day (June 15, 2026) at identical price — suggests coordinated conviction.
  • Company is a clinical-stage biotech with a $6M market cap and limited analyst coverage (86% bullish consensus).

Financial Impact

~$20,000 in insider purchases, representing 0.33% of market cap

insider ownershipmarket sentiment

Risk Factors

  • Micro-cap biotech with high cash burn and no approved products — risk of dilution or failure.
  • Low liquidity and small market cap can amplify volatility.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-PCSA-1781641477400
14 reports for PCSA
Performance horizon
70% Hit rate @ T+5 7 of 10 directional calls Went positive at some point 8 of 11 best @ T+5▲ +19.60%Mar 31, 2026
Filters
Rows
Reports for PCSA — sortable, filterable
TypeNow
Oct 26, 2026
1d ago
EFFECT
BEARISH ★ 6/10
$1.80awaiting T+5—$1.82 (−1.39%)
Oct 22, 2026
5d ago
DEF 14A
NEUTRAL ★ 4/10
$1.81awaiting T+5—$1.82 (+0.55%)
Oct 9, 2026
18d ago
S-3
BEARISH ★ 7/10
$1.90 $1.73▲ +8.95%▲ +7.45%$1.82 (+4.21%)
Jul 29, 2026
12w ago
8-K
MIXED ★ 6/10
$2.03 $2.19▲ +7.88%▲ +2.35%$1.82 (−10.34%)
Jul 1, 2026
16w ago
Insider Cluster
BULLISH ★ 5/10
$2.16 $2.16· 0.00%▼ −1.37%$1.82 (−15.74%)
Jun 16, 2026
19w ago
Insider Cluster
BULLISH ★ 5/10
$2.15 $1.93▼ −10.23%▼ −9.19%$1.82 (−15.35%)
Jun 16, 2026
19w ago
Insider Cluster
BULLISH ★ 4/10
$2.15 $1.93▼ −10.23%▼ −9.19%$1.82 (−15.35%)
Jun 1, 2026
21w ago
Insider Cluster
BULLISH ★ 4/10
$2.92 $2.04▼ −30.31%▼ −27.34%$1.82 (−37.67%)
May 19, 2026
23w ago
Insider Cluster
BULLISH ★ 5/10
$2.61 $2.64▲ +1.15%▼ −0.65%$1.82 (−30.27%)
May 19, 2026
23w ago
Insider Cluster
BULLISH ★ 5/10
$2.61 $2.64▲ +1.15%▼ −0.65%$1.82 (−30.27%)
Showing 10 of 14

US Market Status

Market Closed — Opens Thu (10h 32m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 16, 2026